KPV and Gut Health: What Has Been Studied

What the research covers

KPV has not been tested in people with gut disease. Its gut evidence comes from rodent (mouse), rodent (rat) and lab cell studies. KPV is a three-amino-acid peptide, lysine-proline-valine. It is the tail end, amino acids 11 to 13, of the hormone alpha-MSH.

A 2008 study tested KPV on human gut cells and immune cells in the lab. It lowered their inflammation signals. The cells took KPV in through a transporter called PepT1. In the same study, rodents (mouse) with colitis were given KPV in drinking water. It reduced colitis caused by two chemicals.

A second 2008 study tested KPV in two rodent (mouse) colitis models. Treated rodents (mouse) got better sooner and regained more weight. Their colons showed less inflammation. In 2017, KPV was packed into tiny particles and given by mouth to rodents (mouse) with colitis. This reduced damage to the gut lining and lowered TNF-alpha. A 2021 rodent (rat) study gave KPV in a gel into the rectum. Body weight loss and the disease activity score were reduced. It decreased the proinflammatory cytokines TNF-alpha and interleukin 6.

A PubMed search on 27 September 2026 found no clinical trial of KPV. The search was KPV[tiab] AND clinicaltrial[filter], which returned 0 records. ClinicalTrials.gov listed no KPV trials on the same date. So there are no human data on KPV dose, benefit or safety for IBS, IBD or other gut conditions.

Sources

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). PMID 18061177 doi:10.1053/j.gastro.2007.10.026 Human gut and immune cell lines, plus rodent (mouse) DSS and TNBS colitis with KPV in drinking water.
2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis (2008). PMID 18092346 doi:10.1002/ibd.20334 Rodent (mouse): KPV in DSS colitis and transfer colitis; faster recovery, less colon inflammation.
3. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther (2017). PMID 28143741 doi:10.1016/j.ymthe.2016.11.020 Rodent (mouse): KPV in hyaluronic acid nanoparticles given by mouth reduced colitis damage and TNF-alpha.
4. Hiltz ME, Lipton JM Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J (1989). PMID 2550304 Identifies KPV as the C-terminal tripeptide of alpha-MSH; rodent (mouse) ear-swelling model.
5. Sun J, Xue P, Liu J, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng (2021). PMID 34547895 doi:10.1021/acsbiomaterials.1c00792 Rodent (rat) TNBS colitis: KPV in a hydrogel given rectally eased weight loss and disease scores and lowered TNF-alpha and IL-6.